kyoto.jpeg

kyoto

kyotovisitorshost.jpeg

kyotovisitorshost

General information

Announcements(0)

Overview

Pre-registration

Abstract Submission (Oral/Poster Presentation)

Guidelines for Writing Abstracts (Oral/Poster Pres

Program

Sessions

Search presentations

pharm140_e.png

icon_20251203154432448.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts. If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts. We will reply after confirming that you were a participant. Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Timetable

Discovery of DSP-1053, a novel benzyl piperidine derivative characterized by bromo substituent

A halogen bond (abbreviated as XB) occurs when there is evidence of a net attractive interaction between an electrophilic region associated with a halogen atom in a molecular entity and a nucleophilic region in another, or the same, molecular entity.1) A typical XB is denoted by the three dots in R-XoooY. R-X is the XB donor, where X is any halogen atom with an electron-poor region, and R is a group covalently bound to X. Y is the XB acceptor and is typically a molecular entity possessing at least one electron-rich region. Since XB is highly directional interaction (the angle R-XoooY tends to be close to 180&deg;), it has been played an important role to control the organization of molecules in crystal engineering. Recently, XB donors have attracted much attention as bench-stable organo-Lewis acids in synthetic organic chemistry, and an increasing number of novel XB donors have been developed and reported to date. In addition, it has been identified that XB contributes to the recognition of the halogen-containing drug molecules in vivo, affecting their biological activities. In this symposium, the cutting-edge research of XB, including catalysis and medicinal chemistry, will be presented by the pioneering researchers in Japan, so that further understanding and utilization of XB interaction facilitate the development of drug discovery. 1) Definition of the halogen bond (IUPAC Recommendations 2013), G. R. Desiraju, P. S. Ho, L. Kloo, A. C. Legon, R. Marquardt, P. Metrangolo, P. Politzer, G. Resnati, K. Rissanen, Pure Appl. Chem. 2013, 85, 1711-1713.

Cutting-edge research of halogen bonding including catalysis and drug discovery

The 140th Annual Meeting of the Pharmaceutical Society of Japan (Kyoto)

Presentation Information

[S12-3]Discovery of DSP-1053, a novel benzyl piperidine derivative characterized by bromo substituent

Password required to view